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fficacy and Safety of Torcetrapib,
Novel Cholesteryl Ester Transfer Protein
nhibitor, in Individuals With Below-Average
igh-Density Lipoprotein Cholesterol Levels
ichael H. Davidson, MD, FACC,* James M. McKenney, PHARMD,† Charles L. Shear, DRPH,‡
ames H. Revkin, MD, FACC‡
hicago, Illinois; Richmond, Virginia; and New London, Connecticut
OBJECTIVES This study was designed to evaluate the efficacy and safety of torcetrapib, a cholesteryl ester transfer
protein (CETP) inhibitor, in subjects with low high-density lipoprotein cholesterol (HDL-C) levels.
BACKGROUND Evidence suggests HDL-C is atheroprotective. A proven mechanism for increasing the level
of HDL-C is the inhibition of CETP.
METHODS A total of 162 subjects with below-average HDL-C (men 44 mg/dl; women 54 mg/dl)
who were not taking lipid-modifying therapy were randomized to double-blind treatment
with torcetrapib 10, 30, 60, or 90 mg/day or placebo (30 subjects per group).
RESULTS The percent change from baseline toWeek 8 with torcetrapib (least-squares mean difference from
placebo) was dose-dependent and ranged from 9.0% to 54.5% for HDL-C (p 0.0001 for 30 mg
and higher doses) and from 3.0% to16.5% for low-density lipoprotein cholesterol (LDL-C) (p
 0.01 for 90-mg dose). Low-density lipoprotein cholesterol lowering was less in subjects with
higher (150 mg/dl) versus lower levels of baseline triglycerides; at 60 mg, the change in LDL-C
was 0.1% versus 22.2% (p  0.0001), respectively. Particle size for both HDL and LDL
increased with torcetrapib. There were no dose-related increases in the frequency of adverse
events. Significant blood pressure increases were noted in 2 of 140 subjects.
CONCLUSIONS Torcetrapib resulted in substantial dose-dependent elevations in HDL-C, accompanied by moderate
decreases in LDL-C at the higher doses. Torcetrapib was generally well tolerated. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.067Cardiol 2006;48:1774–81) © 2006 by the American College of Cardiology Foundation
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iigh-density lipoprotein cholesterol (HDL-C) is an inde-
endent inverse risk factor for coronary heart disease
CHD), and elevating HDL-C is a promising strategy for
See page 1791
reventing cardiovascular events. However, the range of
rugs for elevating levels of HDL-C is limited. Statins (1)
nd fibrates (2) provide only modest increases in HDL-C,
nd niacin (3), although more effective, is poorly tolerated.
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aculty: Yale University. Dr. Charles L. Shear—Institution/Employer: Pfizer.The cholesteryl ester transfer protein (CETP) plays a pivotal
ole in cholesterol metabolism, exchanging cholesteryl esters
CEs) and triglycerides between lipoproteins (4). Typically,
ETP transfers CEs from HDL to very low-density lipoprotein
VLDL) and low-density lipoprotein (LDL) in exchange for
riglycerides and transfers triglycerides from VLDL to LDL and
DL in exchange forCEs (4). Thus, CETP activity is potentially
ro-atherogenic, decreasing the CE content of atheroprotective
DL and increasing the CE content of atherogenic VLDL and
DL (4). Furthermore, by exchanging triglycerides in VLDL for
Es inHDL and LDL, CETP promotes the formation of small
ense LDL and HDL by increasing the remodeling of
riglyceride-enriched LDL and HDL particles by triglyceride
ipases (4). Small dense LDL is particularly atherogenic (5). In
ndividuals with elevated triglyceride levels, such as those with
iabetes, the VLDL pool is typically enlarged, and CETP-driven
riglyceride enrichment of HDL and LDL particles may be
specially relevant in creating an atherogenic lipid profile (6,7).
Cholesteryl ester transfer protein inhibition is a potential
trategy for elevating HDL-C and for treating cardiovascular
isease (CVD) (4). In rabbit models, several techniques have been
mployed to suppress CETP activity, resulting in increases in
DL-C and atherosclerotic regression (8–11). Two CETP
nhibitors, JTT-705 and torcetrapib, are in clinical development.
n preliminary trials, torcetrapib has been shown to produce
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November 7, 2006:1774–81 Torcetrapib in Subjects With Low HDLubstantial elevations in HDL-C, modest decreases in LDL
holesterol (LDL-C), and increases in lipid particle size (12,13).
This phase 2 study provides further data on the efficacy and
afety of torcetrapib in a large group of individuals with below-
verage levels of HDL-C. A study of torcetrapib administered on
background of atorvastatin to similar subjects is reported in this
ssue of the Journal (see page 1782).
ETHODS
tudy design. This was a multicenter study (23 centers). Fol-
owing screening, eligible participantswere randomized to 8weeks
f double-blind treatment with either placebo or torcetrapib 10,
0, 60, or 90 mg once daily (Fig. 1).
articipants. Eligible participants were ages 18 to 65 years with
ow HDL-C levels (44 mg/dl for men and 54 mg/dl for
omen) at screening (14). Exclusion criteria included major/
nstable concurrent illnesses, lipid-altering therapy within 30 days
f screening, and an LDL-C level of190 mg/dl or triglycerides
400 mg/dl during screening.
The protocol was approved by the Institutional Review Board
r Independent Ethics Committee at each site andwas conducted
n compliance with the Declaration of Helsinki.
Abbreviations and Acronyms
AE  adverse event
apo  apolipoprotein
CE  cholesteryl ester
CETP  cholesteryl ester transfer protein
CHD  coronary heart disease
CVD  cardiovascular disease
DBP  diastolic blood pressure
HDL-C  high-density lipoprotein cholesterol
LDL-C  low-density lipoprotein cholesterol
NMR  nuclear magnetic resonance
SBP  systolic blood pressure
VLDL-C  very low-density lipoprotein cholesterol
igure 1. Schematic representation of study design and numbers of subjects. Sam
ielding 80% power to detect a 25% treatment difference in high-density lipoprotein cho
test with 5% type I error. LOCF last observation carried forward (i.e., subjects with baipid assessments. The primary end point was the percent
hange from baseline in the levels of HDL-C after 8 weeks.
bsolute changes from baseline in HDL-C and percent changes
nd absolute changes in LDL-C, triglycerides, and total choles-
erol were secondary end points. Additional lipid analyses included
polipoprotein concentrations;HDLparticle type;HDL,VLDL,
nd LDL subclass composition; phospholipid concentrations; and
uclear magnetic resonance (NMR) lipoprofile.
nalytical methods. Biochemical analyses were performed by
edical Research Laboratories (Highland Heights, Kentucky).
otal cholesterol and net triglycerides were quantified by a
DC-standardized enzymatic assay in an automated chemistry
nalyzer. High-density lipoprotein cholesterol was measured by
eparatingHDL fromLDL/VLDL by heparin/MnCl2 chemical
recipitation. Low-density lipoprotein cholesterol and VLDL
holesterol (VLDL-C) were estimated by the Friedewald formula
15). If total triglycerides were 400 mg/dl, LDL-C and
LDL-C were measured directly by beta-quantification using
ltracentrifugation. Phospholipid was measured by an automated
nzymatic colorimetric method. High-density lipoprotein sub-
lasses (HDL2 and HDL3) were separated by zonal ultracentrif-
gation. Apo A-I, A-II, and B-100 were analyzed by an auto-
ated immunoturbidimetric procedure. Lipoprotein subclasses
here determined using proton NMR by Liposciences Inc.
Raleigh, North Carolina) (16).
afety assessments. Safety assessments included a physical
xamination and measurement of vital signs, electrocardiograms,
nd standard laboratory safety tests. All adverse events (AEs) were
ecorded.
tatistical analyses. The primary statistical analysis for
fficacy included all randomized participants who received at
east 1 dose of study treatment with at least 1 before- and
fter-treatment end point measurement using the last-
bservation-carried-forward approach. The analysis of the
rimary end point (HDL-C percent change from baseline at
eek 8) employed analysis of covariance using a linear
odel that included a term for treatment group and baseline
ize was calculated based on earlier torcetrapib studies, with 25 subjects per groupple s
lesterol (HDL-C), assuming a common standard deviation of 30.5% and 2-sided
seline and at least one post-baselineHDL-Cmeasurement); R randomization.
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Torcetrapib in Subjects With Low HDL November 7, 2006:1774–81alue as a continuous covariate (SAS Proc Mixed). Study
enter was not included as an independent variable. Least-
quares means (LS means) were computed and pairwise
reatment comparisons of torcetrapib dose group versus
lacebo were assessed for statistical significance at the p 
.05 level (2-sided) using a step-down procedure to preserve
he type 1 error across the multiple comparisons (17). A
5% confidence interval (CI), unadjusted for multiplicity,
as calculated for each pairwise comparison. Similar anal-
ses were performed for secondary end points.
For lipid assessments, results are presented in figures as
aw means for each time point. The percent changes in
ipids at 8 weeks used for hypothesis testing are presented in
abular form.
For vital signs, each patient’s complement of after-
aseline observations was averaged and a change from
aseline was calculated. This measure was then analyzed in
manner analogous to the efficacy parameters discussed
arlier; that is, ANCOVA was employed using SAS Proc
ixed with a linear model, including a term for treatment
roup and baseline value as a continuous covariate. Least-
quares means were calculated and 95% CIs were computed
or the within-treatment-group change from baseline.
ESULTS
aseline demographics. Baseline demographic characteristics
able 1. Baseline Patient Demographics and Lipid Parameters
Parameter Placebo
emographics
n 32
Men, n (%) 25 (78)
Mean age, years (SD)
Men 47 (10)
Women 45 (11)
Race or ethnicity, n (%)
White 27 (84)
Black 0 (0)
Hispanic 4 (13)
Other 1 (3)
ean BMI, kg/m2
Men 29.4
Women 32.8
ean SBP/DBP, mm Hg 123.0/78.4
ipid parameters
n 32
Mean HDL-C, mg/dl (SD)* 39 (7)
% 40 mg/dl 59
Mean LDL-C, mg/dl (SD)* 125 (31)
% 130 mg/dl 59
Mean TGs, mg/dl (SD)* 186 (84)
% 150 mg/dl 38
Mean TC, mg/dl (SD)* 201 (36)
% 200 mg/dl 44
Ratio of LDL-C to HDL-C (SD)* 3.2 (0.8)
Baseline values are the average of the last 2 measurements made within the 2 week
BMI  body mass index; DBP  diastolic blood pressure; HDL-C  high-dens
lood pressure; TC  total cholesterol; TGs  triglycerides.nd lipid profiles of the randomized participants (n 162) were cell balanced across treatment groups (Table 1). Mean HDL-C
evels for treatment groups ranged from 37 to 40 mg/dl.
fficacy: lipid parameters. HDL AND HDL-RELATED APO-
IPOPROTEINS. Torcetrapib dose-dependently increased
DL-C levels (Table 2, Fig. 2). Percent changes in HDL-C
rom baseline to Week 8 ranged from 9.0% to 54.5% with
orcetrapib 10 to 90 mg/day (LS mean difference from placebo).
ifferences were significant at doses of 30, 60, and 90 mg/day (p
0.0001). Increases in HDL-C were accompanied by dose-
ependent increases in the levels of apo A-I and apo A-II, with
po A-I being the dominant change (Table 3).
Ultracentrifugation/precipitation analysis showed that torce-
rapib increased HDL particles of larger size (Table 3). High-
ensity lipoprotein subclass changes determined by NMR spec-
roscopy were consistent with the findings from
ltracentrifugation/precipitation analysis showing that torcetrapib
roduced dose-dependent increases in levels of the large HDL-C
ubclasses. At the 60-mg and 90-mg doses of torcetrapib, large
DL-C (8.3 to 13 nm) increased from 12.5 (SD 5.6) to 26.9
g/dl (SD 11.3) (p 0.05) and 13.2 (SD 6.3) to 35.0mg/dl
SD  21.3) (p  0.01), respectively. At these same doses of
orcetrapib, mean HDL particle size also increased from 8.3
0.3) to 8.8 nm ( 0.4) and 8.3 (0.3) to 9.0 nm (0.5),
espectively (p  0.0001 for both).
PO B-RELATED LIPOPROTEINS. At Week 8, moderate de-
Torcetrapib (mg/day)
0 30 60 90
31 34 33
69) 26 (84) 27 (79) 27 (82)
12) 45 (10) 46 (10) 49 (11)
9) 41 (8) 48 (10) 49 (10)
78) 26 (84) 28 (82) 30 (91)
0) 1 (3) 3 (9) 1 (3)
22) 4 (13) 3 (9) 2 (6)
0) 0 (0) 0 (0) 0 (0)
.4 29.3 29.6 31.1
.6 35.1 34.6 33.3
/76.6 119.0/78.0 120.0/77.6 120.4/76.5
30 34 33
5) 37 (5) 37 (6) 37 (6)
77 62 67
28) 117 (27) 120 (22) 127 (29)
63 68 52
63) 205 (88) 192 (88) 197 (78)
33 35 24
35) 194 (32) 194 (29) 204 (30)
57 59 45
0.9) 3.2 (0.8) 3.3 (0.7) 3.5 (0.9)
e first treatment dose.
oprotein cholesterol; LDL-C  low-density lipoprotein cholesterol; SBP  systolic1
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November 7, 2006:1774–81 Torcetrapib in Subjects With Low HDLbserved with torcetrapib 60mg (8.1%) and 90mg (16.5%; p
0.01) (Table 2, Fig. 3). At these doses, LDL-C decreases were
ccompanied by significant (p  0.01) decreases in apo B-100
evels, suggesting a reduction in the concentration of circulating
DL particles (Table 3). Interestingly, LDL-C lowering with
orcetrapib was less apparent in subjects with high baseline
riglycerides (150mg/dl) comparedwith thosewith low baseline
riglycerides 150 mg/dl (Table 4).
Nuclear magnetic resonance analysis demonstrated a
rend to reduction in the concentration of the small LDL-C
ubclass. Torcetrapib 60 mg and 90 mg decreased small
DL-C (18.3 to 19.7 nm) from 35.6 (SD  39.5) to 11.9
g/dl (SD  17.3) and from 42.1 (SD  44.2) to 10.3
g/dl (SD 12.0), respectively (pNS for both). Nuclear
agnetic resonance spectroscopy showed LDL particle size
able 2. Change in Standard Lipid Parameters
Mean Values at Baseline and
Lipid Parameter Placebo 10
DL-C 39, 39 40, 4
DL-C 125, 127 128, 1
riglycerides 186, 204 176, 1
otal cholesterol 201, 207 202, 2
atio LDL-C/HDL-C 3.2, 3.3 3.3, 3
atio apo B-100/apo A-I 1.0, 1.0 1.0, 1
Percent Change From Baseline at Week 8 (LS Mean
Lipid Parameter 10
DL-C (95% CI) 9.0 (2.8, 20.8) 27
DL-C (95% CI) 1.1 (10.2, 8.0)
riglycerides (95% CI) 11.9 (29.0, 5.2) 
otal cholesterol (95% CI) 0.9 (6.5, 4.7)
atio LDL-C/HDL-C (95% CI) 9.5* (18.2, 0.9) 16
atio apo B-100/apo A-I (95% CI) 5.2 (13.2, 2.7) 10
p  0.05; †p  0.01; ‡p  0.0001.
apo  apolipoprotein; CI  confidence interval; LOCF  last observation carrieFigure 2. Mean change in high-density lipoprotein cholesteroas increased in a dose-dependent manner. Torcetrapib 60
g and 90 mg increased mean LDL particle size from 20.4
0.7) to 21.2 nm (0.6) and 20.4 (0.7) to 21.3 nm
0.6), respectively (p  0.0001 for both).
Very low-density lipoprotein cholesterol levels showed a dose-
esponsive decrease from baseline, with a maximal change of
25% with torcetrapib 90 mg at week 8. Very low-density
ipoprotein cholesterol phospholipid levels, triglyceride levels, and
ubclass sizing patterns did not demonstrate any consistent dose-
elated trends.
Changes in non–HDL-C levels at week 8 were consistent
ith changes in apo B-100 levels (Table 3).
OTAL CHOLESTEROL, TRIGLYCERIDES, AND LIPID
ATIOS. There were no appreciable changes in total cholesterol
k 8 (Baseline, Final mg/dl)
Torcetrapib (mg/day)
30 60 90
37, 47 37, 53 37, 58
117, 122 120, 115 127, 108
205, 211 192, 172 197, 184
194, 209 194, 202 204, 202
3.2, 2.7 3.3, 2.3 3.5, 2.1
1.0, 0.9 1.0, 0.8 1.1, 0.8
rences Relative to Placebo Using LOCF Approach)
Torcetrapib (mg/day)
30 60 90
5.5, 39.6) 45.1‡ (33.4, 56.9) 54.5‡ (42.8, 66.3)
6.3, 12.3) 8.1 (17.1, 0.9) 16.5† (25.5, 7.4)
21.5, 13.3) 16.1 (32.9, 0.8) 17.8 (34.8, 0.8)
0.8, 10.6) 0.3 (5.2, 5.8) 3.8 (9.3, 1.8)
25.7, 8.1) 34.9‡ (43.4, 26.3) 43.3‡ (51.9, 34.7)
18.5, 2.44) 21.5‡ (29.3, 13.7) 31.2‡ (39.2, 23.3)
ard; LS  least squares; other abbreviations as in Table 1.Wee
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Torcetrapib in Subjects With Low HDL November 7, 2006:1774–81evels. Total triglyceride levels were generally decreased in
orcetrapib-treated subjects relative to placebo, although there was
ariability in response over course of the study (Table 2). Dose-
elated decreases in the LDL-C/HDL-C ratio (Table 2, Fig. 4)
nd the apo B-100/apo A-I ratio (Table 2) were consistent with
he observed decreases in LDL-C and increases in HDL-C.
AFETY AND TOLERABILITY. Torcetrapib was generally well
olerated (Table 5). Treatment-related discontinuations were rare.
wo subjects withdrew from the study permanently: 1 because of
evere diarrhea and vomiting that resolved following permanent
able 3. Change in Other Lipid Parameters
Mean Values at Baseline and
Parameter Placebo 10
ipoproteins
Apo A-I 131.0, 129.5 133.5, 139.9
Apo A-II 31.4, 30.7 31.2, 31.3
Apo B-100 129.6, 132.2 131.3, 134.5
Non–HDL-C 162.2, 167.3 162.9, 162.3
ltracentrifugation/precipitation
analysis
HDL-2 cholesterol 11.7, 11.1 12.0, 13.1
HDL-3 cholesterol 27.7, 27.9 28.3, 30.2
Percent Change From Baseline at Week 8 (LS Mean
Parameter 10
ipoproteins
Apo A-I (95% CI) 6.0 (1.4, 13.5)
Apo A-II (95% CI) 2.0 (3.4, 7.3)
Apo B-100 (95% CI) 0.5 (6.0, 7.1)
Non–HDL-C (95% CI) 3.4 (10.6, 3.8)
ltracentrifugation/precipitation
analysis
HDL-2 cholesterol (95% CI) 14.1 (17.7, 45.9
HDL-3 cholesterol (95% CI) 7.5 (1.8, 16.8)
p  0.05; †p  0.01; ‡p  0.0001.
Abbreviations as in Table 2.Figure 3. Mean change in low-density lipoprotein cholesteroiscontinuation from treatment (torcetrapib 30 mg/day) and 1
ecause of mild asymptomatic abnormal liver function tests that
esolved without intervention following discontinuation from
reatment (placebo). Two subjects receiving torcetrapib 90mg/day
ithdrew from the study temporarily because of treatment-related
Es (gastroesophageal reflux disease and rash) but resumed
reatment and completed the study without recurrence of the AE.
The incidence of all-causality AEs was similar across
lacebo and torcetrapib treatment groups, with no evidence
f a dose-related response (Table 5). Most treatment-
k 8 (Baseline, Final mg/dl)
Torcetrapib (mg/day)
30 60 90
130.4, 144.8 128.0, 146.9 130.0, 160.2
31.2, 34.1 30.9, 35.0 31.8, 35.6
127.7, 131.9 129.2, 121.7 135.6, 117.9
157.2, 162.3 157.6, 149.1 166.3, 143.4
11.2, 14.6 10.9, 17.5 11.5, 22.6
26.5, 32.1 26.2, 35.3 26.2, 36.5
rences Relative to Placebo Using LOCF Approach)
Torcetrapib (mg/day)
30 60 90
12.3† (4.7, 19.8) 15.8‡ (8.4, 23.1) 23.5‡ (16.1, 31.0)
11.3‡ (5.9, 16.8) 14.4‡ (9.1, 19.6) 14.3‡ (8.9, 19.6)
1.0 (5.7, 7.6) 8.5† (15.0, 2.1) 15.5‡ (22.0, 8.9)
0.2 (7.5, 7.1) 9.8† (16.9, 2.7) 18.0‡ (25.1, 10.8)
34.2* (1.9, 66.6) 66.9‡ (35.5, 98.3) 108.0‡ (76.2, 140.8)
19.1† (9.6, 28.5) 30.9‡ (21.7, 40.1) 35.8‡ (26.4, 45.1)Wee
Diffe
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November 7, 2006:1774–81 Torcetrapib in Subjects With Low HDLelated AEs were mild or moderate, with headache, diar-
hea, and flatulence being the most common. There were no
reatment-related serious AEs or deaths.
Laboratory test abnormalities showed no dose-related
rends. One subject receiving placebo demonstrated elevated
iver transaminase levels (alanine aminotransferase/aspartate
minotransferase 3.0  upper limits of normal [ULN])
nd was withdrawn from treatment. No subject had creatine
inase elevations 10.0  ULN (Table 5).
Although in some treatment groups at Week 8 there were
levations from baseline in systolic and diastolic blood
ressure (SBP and DBP), over the course of the study,
hanges from baseline in SBP and DBP were highly variable
n all treatment groups, with no evidence of a dose-response
elationship with torcetrapib (Fig. 5). When all follow-up
easures were averaged, mean SBP changes ranged from
0.2 mm Hg (placebo group) to 1.3 mm Hg (torcetrapib
0-mg group), with none of the changes in any group
chieving statistical significance (all 95% CIs overlapped
ero) (Table 6). Mean DBP changes ranged from0.7 mm
g (torcetrapib 10-mg group) to 0.9 mm Hg (torcetrapib
0-mg group); again, no change in any group was significant
Table 6).
Of the patients receiving torcetrapib, 1.6% (2 of 129)
xperienced elevations in blood pressure defined as 1)
BP 15 mm Hg or DBP 10 mm Hg from baseline at 3
onsecutive visits or 2) SBP 180 mm Hg with a 20 mm
able 4. Mean Percent Change (95% CI) in LDL-C Analyzed b
o Placebo at Week 8, LOCF)
10 30
G 150 mg/dl 0.8 (9.5, 11.1) 2.9 (14.
n 13 10
G 150 mg/dl 1.5 (14.1, 11.0) 6.8 (5.6
n 19 20
p  0.0001.
Abbreviations as in Table 2.Figure 4. Change in low-density/high-density lipoprotein cholesterol (Lg change from baseline or DBP105 mmHg with a15
m Hg change from baseline at a single visit. No subject
ermanently discontinued treatment because of elevated
lood pressure.
ISCUSSION
his study provides further information about the lipid-
odifying benefits and safety of torcetrapib. In individuals
ith low HDL-C levels, torcetrapib 30 to 90 mg/day
esulted in substantial and significant dose-dependent ele-
ations in HDL-C (54.5% at 90-mg dose) and, at higher
oses, moderate decreases in LDL-C (16.5% at 90-mg
ose). These changes in HDL and LDL are consistent with
rior reports of torcetrapib (12,13).
Of importance, albeit post-hoc and in non-randomized
ubgroups, was the observation that LDL-C lowering with
orcetrapib was almost completely lost in subjects with high
aseline triglyceride levels. This suggests that CETP inhi-
ition may be of limited utility as a monotherapy in those
ith high triglycerides (a highly prevalent concurrent pre-
entation in those with low HDL and/or metabolic syn-
rome) requiring LDL lowering. One explanation may be
hat compositional changes in VLDL-1, in the presence of
ETP inhibition, may lead to enhanced conversion of
LDL to LDL via lipoprotein lipase. Without correspond-
ng up-regulation in LDL receptor activity, there may be an
seline Total Triglyceride Levels (LS Mean Difference Relative
Torcetrapib (mg/day)
60 90
) 22.2 (32.7, 11.6)* 32.9 (44.3, 21.4)*
12 9
) 0.1 (12.0, 12.2) 10.3 (22.2, 1.5)
22 24y Ba
0, 8.3
, 19.2DL-C/HDL-C) ratio over the course of the study—all subjects.
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ay resolve this issue, which would support strategies to
dminister torcetrapib with a statin.
Ultracentrifugation/precipitation analysis conducted dur-
ng this study suggests that torcetrapib affects both the
umber and size of circulating HDL and LDL particles.
ncreases in the levels of apo A-I and A-II and increases in
DL2 and HDL3 cholesterol are indicative of increased
umbers of the larger subspecies of HDL particles. This was
onfirmed by NMR HDL subclass analysis. Conversely,
Table 5. Summary of Safety—Number of Subj
Placebo
(n  32)
Treatment-related withdrawals 1 (3)
Subjects with AEs
All-causality 24 (75)
Treatment related 6 (19)
Serious AEs
All-causality 0 (0)
Treatment related 0 (0)
(n  32)
Clinical laboratory tests
ALT/AST 3  ULN 1 (3)
CK  10  ULN 0 (0)
*Both subjects were only temporarily discontinued from trea
AEs  adverse events; ALT  alanine aminotransferase;
upper limit of normal.s
igure 5. Least-squares mean change in systolic (A) and diastolic (B)
lood pressure over the course of the study.ecreases in apo B are indicative of a reduction in the
umber of circulating LDL particles. Nuclear magnetic
esonance analysis showed that torcetrapib also increased
he size of LDL particles.
The effect of torcetrapib on LDL particle size may be
articularly important in reducing atherosclerosis, as the
haracteristics of small dense LDL make it more athero-
enic than larger, less dense LDL (5). Even if there was no
ignificant effect of torcetrapib on HDL-C levels, the effects
n LDL-C, including modest decreases in overall levels and
shift in particle size from small to large, might be expected
o provide benefit.
In addition to further elucidating the beneficial effects of
orcetrapib on lipid metabolism, this trial provides impor-
ant safety data. Generally, torcetrapib was well tolerated,
iscontinuations from treatment were rare, there were no
pparent dose-related trends in the incidences of AEs, and
ost AEs were mild or moderate in nature. Although
reviously published studies of torcetrapib have not reported
ffects on blood pressure (12,13), increases in blood pressure
ere observed in some individuals in this study. However,
he lack of a consistent treatment-related pattern over time
nd dose suggests the effect to be of limited magnitude
ithin this dose range. Further studies are underway to
efine the magnitude and clinical relevance of these blood
ressure changes.
The link between lower LDL-C levels and decreased
ardiovascular risk has been clearly demonstrated in CVD
revention trials with statins (18). Furthermore, recent
tatins trials provide evidence that aggressive versus moder-
te LDL lowering is associated with additional benefits
19,20). Yet there is less clinical trial data showing the
enefits of increasing HDL-C levels and a distinct paucity
f clinical trial data to show the impact of aggressively
levating HDL-C on clinical end points. This may partly be
ue to the current lack of well-tolerated drugs that can
(%)
Torcetrapib (mg/day)
0 30 60 90
32) (n  31) (n  34) (n  33)
0) 1 (3) 0 (0) 2 (6)*
59) 19 (61) 22 (65) 18 (55)
25) 6 (19) 4 (12) 7 (21)
0) 1 (3) 0 (0) 0 (0)
0) 0 (0) 0 (0) 0 (0)
34) (n  37) (n  31) (n  33)
0) 0 (0) 0 (0) 0 (0)
0) 0 (0) 0 (0) 0 (0)
and completed the study.
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November 7, 2006:1774–81 Torcetrapib in Subjects With Low HDLuidelines for CVD prevention recognize low HDL-C
evels as a risk factor, they continue to place most emphasis
n decreasing LDL-C levels (22). This fact, combined with
he relatively modest decreases in LDL-C observed with
orcetrapib and JTT-705, means that CETP inhibitors are
ikely to be used in combination with statin therapy. A
eparate phase 2 study evaluating the efficacy and safety of
orcetrapib when administered on a background of atorva-
tatin to subjects with below-average HDL-C levels is
eported in this issue of the Journal.
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